middle.news
Radiopharm Theranostics Hits 93% Success in RAD 101 Trial, Plans Phase 3 Launch
11:19am on Friday 31st of July, 2026 AEST
•
Healthcare
Read Story
Radiopharm Theranostics Hits 93% Success in RAD 101 Trial, Plans Phase 3 Launch
11:19am on Friday 31st of July, 2026 AEST
Key Points
RAD 101 Phase 2b trial hits 93% primary endpoint concordance
Phase 3 registrational trial planned for Q4 2026
RAD 204 Phase 1 shows durable partial response in advanced cancers
Quarter-end cash fell to $4.1 million with $15 million quarterly burn
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE